Walleye Capital’s Edwards Lifesciences EW Stock Holding History

Walleye Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.96M	Buy	49,500 +17,400	+54%	+$1.43M	0.02%	956
2025 Q4	$2.74M	Buy	32,100 +25,400	+379%	+$2.08M	0.01%	1609
2025 Q3	$521K	Buy	6,700 +6,300	+1,575%	+$492K	﹤0.01%	2570
2025 Q2	$31.3K	Sell	400 -31,600	-99%	-$2.36M	﹤0.01%	4159
2025 Q1	$2.32M	Sell	32,000 -10,300	-24%	-$737K	0.01%	1309
2024 Q4	$3.13M	Buy	42,300 +20,700	+96%	+$1.45M	0.01%	1395
2024 Q3	$1.43M	Sell	21,600 -17,600	-45%	-$1.28M	﹤0.01%	2281
2024 Q2	$3.62M	Buy	39,200 +21,600	+123%	+$1.91M	0.01%	1546
2024 Q1	$1.68M	Sell	17,600 -56,900	-76%	-$4.78M	﹤0.01%	2125
2023 Q4	$5.68M	Buy	74,500 +37,900	+104%	+$2.64M	0.01%	1022
2023 Q3	$2.54M	Sell	36,600 -8,100	-18%	-$651K	0.01%	1548
2023 Q2	$4.22M	Buy	44,700 +18,600	+71%	+$1.62M	0.02%	842
2023 Q1	$2.16M	Buy	+26,100	New	+$2.05M	0.03%	676
2019 Q3	–	Sell	-42,600	Closed	-$2.62M	–	1986
2019 Q2	$2.62M	Buy	42,600 +35,400	+492%	+$2.14M	0.29%	52
2019 Q1	$459K	Buy	+7,200	New	+$411K	0.08%	413

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Walleye Capital's EW Position: Q1 2026 in Review

Walleye Capital reduced its Edwards Lifesciences (EW) stake by 99% in Q1 2026, selling an estimated $22.3M and leaving 1,950 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #3471.

Walleye Capital first reported a position in EW in Q1 2019 and has held it in 13 quarters since. The position peaked at $23.3M in Q4 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Walleye Capital held 1,950 shares of Edwards Lifesciences worth $156K as of Q1 2026.
Walleye Capital sold 270,921 Edwards Lifesciences shares in Q1 2026, an estimated $22.3M.
Edwards Lifesciences made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3471 holding.
Walleye Capital first reported a position in Edwards Lifesciences in Q1 2019 and has held it in 13 quarters since.
Walleye Capital's Edwards Lifesciences position peaked at $23.3M in Q4 2025.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.